Breast Cancer Female
Conditions
Keywords
breast cancer risk, risk perceptions, screening intentions
Brief summary
The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.
Detailed description
The Understanding and Addressing Rejection of Personalized Cancer Risk Information study seeks to understand the nature of the phenomenon of personalized cancer risk rejection in the context of mammography screening by testing hypotheses about why women reject their risk estimate and the influence of rejection on screening intentions. The Breast Cancer Risk Assessment Tool (BCRAT) will be used to asses participant's breast cancer risk. This model is designed to estimate breast cancer risk in women 35-84, and uses the following predictors: 1) age, 2) age at first menstrual period, 3) age at first live birth, 4) first-degree relatives with breast cancer, 5) previous breast biopsy with atypical hyperplasia, and 6) race/ethnicity. Participants will be required to complete a survey in which they receive their BCRAT model risk estimate and respond to that risk estimate.
Interventions
BEHAVIORALPresentation of a personal breast cancer risk estimate
Participants answer questions that are used to calculate their personal breast cancer risk using the Gail Model. This risk estimate is presented to participants using written text and an icon array.
Sponsors
University of Colorado, Denver
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
39 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
1. Female sex 2. Age 39-74 (i.e., people who are eligible for routine breast cancer screening and for whom guidelines recommend an informed, risk-based decision) 3. English literacy 4. Black or African American race
Exclusion criteria
1\. Prior diagnosis of 1. breast cancer 2. Ductal carcinoma in situ (DCIS) 3. Lobular carcinoma in situ (LCIS) 4. Known BRCA1/2 gene mutation 5. Cowan syndrome 6. Li-Fraumeni syndrome 7. Having received previous chest radiation for treatment of Hodgkin's lymphoma.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Rejected the Cancer Risk Estimate | at baseline survey | Participants are asked whether they agree or disagree with their Gail Model risk estimate. Risk rejection was defined as disagreement the estimate. An open text box allows them to write the risk number that they believe is accurate for them. |
| Risk-concordant Information Seeking | at baseline survey | Participants will be given the opportunity to get more information about breast cancer screening, and will be given response options to receive information for women at lower than average risk, higher than average risk, or women with risk that is "about the same as a typical woman". Concordance is measured by agreement between the participants' actual risk estimate and the option that they choose. |
| Screening Intentions | at baseline survey | Screening intentions were measured on a 5-point Likert scale. 1=definitely will not, 2=probably will not, 3=maybe, 4=probably will, 5=definitely will. Higher scores indicate greater intention. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORLaura D Scherer, PhD
University of Colorado, Denver
PRINCIPAL_INVESTIGATORErika Waters, PhD
Washington University School of Medicine
Participant flow
Recruitment details
Participants were recruited to this one-time online survey using Dynata, an online survey panel
Pre-assignment details
There were 836 participants who were eligible to take the survey based on screener questions and began the survey. 781 participants met eligibility criteria and were included in the enrollment population.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 55.8 Years STANDARD_DEVIATION 9.63 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 781 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Sex: Female, Male Female | 781 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
None listed